In order to thoroughly implement the major decisions and deployments of the provincial Party committee, provincial government, municipal party committee, and municipal government, the implementation of the work of "Enterprise innovation incubation must visit" is promoted.
On the afternoon of February 21, Zhu Limin, the Standing Committee of the Municipal Committee and the Minister of Publicity Department, and Feng Hanting, the deputy mayor of the Municipal government, came to our company to carry out the "six must-visit" work research. Mr. Wang Youwei, general manager of Baiyinkang Yuxin Biotechnology Co., LTD., received the research. Focus on understanding production and operation, technology research and development, talent introduction, industry-university-research cooperation, achievement transformation, etc., listen to our opinions and suggestions, and fully grasp the difficulties, problems and needs of enterprise scientific and technological innovation and management.
Zhu Limin and Feng Han recognized our company's development achievements, encouraging us to firmly develop confidence, seize development opportunities, focus on market demand, position quasi-development, improve quality and efficiency through technological transformation, increase production and capacity expansion, etc., and promote enterprise development to a new level. It is necessary to cultivate and build its own brand, enhance brand image and added value of products, increase enterprise publicity, and enhance market competitiveness; To pay attention to marketing, online and offline joint efforts; We should actively participate in all kinds of job fairs, accurately publish employment needs, and cooperate with high-end talents through flexible recruitment methods. It is necessary to effectively enhance the awareness of production safety and environmental protection, produce according to law and regulations, constantly improve the level of enterprise management, and continue to make enterprises bigger, stronger and better.
Kang Yu Xin biological
Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.
The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first domestic enterprise to develop a broad spectrum antiviral new drug "Fapiravir", was shortlisted in the eighth batch of key protection enterprises for epidemic prevention materials in Gansu Province. Kangyuxin won the Excellence Award of the 10th China Innovation and Entrepreneurship Competition National Biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.
